- 作者：D. Pratil ; M. T. Bardella ; M. Peracchi ; L. Porretti ; M. Cardillo ; C. Pagliari ; C. Tarantino ; E. Della Torre ; M. Scalamogna ; P. A. Sianchi ; G. Sirchia ; D. Conte ; North Italy Transplant Programme Working Group (NITp)
- 刊名：Digestive and Liver Disease
- 出版年：2002
- 出版时间：January 2002
- 年：2002
- 卷：34
- 期：1
- 页码：39-43
- 全文大小：658 K
Aims. To assess the frequency of anti-endomysial antibodies, the marker for coeliac disease, in patients with different forms of heart failure, and to establish the clinical features of those endomysial antibody positive.
Subjects and Methods. A total of 642 consecutive patients entering the waiting list for heart transplantation from 1995 through 1997 were studied. The prevalence of endomysial IgA antibodies, determined by indirect immunofluorescence, was compared to that observed in three surveys conducted in the Italian general population.
Results. Of the 642 patients, 12 (1.9 % ; 95 % confidence interval 0.97–3.2) resulted endomysial antibody positive, versus healthy controls (0.35 % ; 95 % confidence interval, 0.23–0.47), accounting for a relative risk of 5.3 (95 % confidence interval, 2.8–10.3). Anti-endomysial antibodies were found in patients with dilated cardiomyopathy and with other forms of heart failure (2.2 % versus 1.6 % ; 95 % confidence interval 0.8–4.7 and 0.6–3.5), with no statistical difference. The 12 endomysial antibody positive patients were leaner (body mass index, 22.0±1.9 vs 24.2±3.1, p<0.05) than 36 seronegative patients matched for baseline demographics and aetiology of cardiomyopathy No differences were observed as regards clinical, biochemical and echocardiographic features, mortality in waiting list and 2-year post-transplant survival.
Conclusions. Patients with end-stage heart failure are at increased risk for coeliac disease as compared to the general population.